Document is current
Any future updates will be listed below
-
Authors
Nógrádi, Bernát https://orcid.org/0000-0001-8643-0367
Molnár, Kinga
Kristóf, Rebeka
Horváth, Orsolya
Huang, Yu-Ting
Ridgway, Zara https://orcid.org/0009-0007-3936-5428
Elicegui, Amaia https://orcid.org/0000-0003-4782-6005
Fuertes-Alvarez, Sandra
Alonso-Martin, Sonia https://orcid.org/0000-0002-3254-0365
Szebeni, Gábor J.
Gémes, Nikolett
Ramadan, Abdullah
Smith, Hannah L. https://orcid.org/0000-0003-3670-5881
Krizbai, István A.
Patai, Roland
Siklós, László
Klivényi, Péter https://orcid.org/0000-0002-5389-3266
Chaytow, Helena https://orcid.org/0000-0003-2257-7620
Gillingwater, Thomas H. https://orcid.org/0000-0002-0306-5577
-
Funding
Funding for this research was provided by:
MND Scotland (2021/MNDS/RP/8430GILL)
- License Information
-
More Information
Article History
Received: 7 November 2024
Accepted: 17 July 2025
First Online: 1 August 2025
Competing interests
: T.H.G. has provided advisory services for Roche and Novartis. S.A.-M. is a named inventor on a patent related to neurological disorders (PCT/EP2021/064274 and US 2024/0277695 A1), entitled “FOXO inhibitors for use in the treatment of diseases caused by abnormal processing of TDP-43 and/or FUS proteins”, not related to this study. SA-M also has ownership in Miaker Developments S.L., a startup related with a pipeline on Neurodegenerative and Neuromuscular Diseases. There are no other competing interests.
